Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections

Core Viewpoint - Inspira Technologies announced positive initial results from its collaboration with Ennocure MedTech to develop a novel bio-electronic treatment aimed at preventing bloodstream infections in critical patients [1][3] Group 1: Technology and Testing Results - The bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours during ex-vivo porcine skin model testing, with continued effectiveness observed over a 24-hour period [2] - The technology utilizes physical electric stimulation instead of chemical agents, showing promising results in preventing pathogen growth on treated surfaces [2][8] - Testing followed standardized protocols, including the AATCC TM100 standard for antimicrobial performance, showing consistent bacterial reduction under active patches compared to controls [3] Group 2: Market Potential and Company Overview - There are an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide each year, indicating a significant market opportunity for the new technology in critical care settings [3] - Inspira Technologies is focused on innovative medical technology in life support and respiratory treatment, with its INSPIRA™ ART system targeting the $19 billion mechanical ventilation market [5] - The company has developed the HYLA™ blood sensor technology for continuous, real-time blood monitoring, targeting the$2.5 billion blood gas analyzer market [5]